DavidStephenTermanMD

Internal Medicine • Pebble Beach, CA

Allergy & Immunology

Physician

Join to view full profile

Dr. Terman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Terman's full profile

Already have an account?

Office
3183 Palmero Way
Pebble Beach, CA 93953
Phone+1 831-624-8569

Education & Training

University of Colorado School of Medicine/National Jewish Health (Adult)Fellowship, Allergy and Immunology, 1968 - 1969
University of Alabama Medical CenterResidency, Internal Medicine, 1966 - 1968
Georgetown University School of MedicineClass of 1966

Certifications & Licensure

CA State Medical License 1972 - 2026
AZ State Medical License 1984 - 2009
CO State Medical License 1973 - 2009
TX State Medical License 1977 - 2009

Publications & Presentations

PubMed

111 citations
Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metast...
Beth A. Pulaski, David S. Terman, Saleem A. Khan, Eric Muller, Suzanne Ostrand-Rosenberg
Cancer Research. 2000-05-15
52 citations
Intrapleural Staphylococcal Superantigen Induces Resolution of Malignant Pleural Effusions and a Survival Benefit in Non-Small Cell Lung Cancer
Shaohua Ren, David S. Terman, Greg Bohach, Abraham Silvers, Chris Hansen
Chest. 2004-11-01
54 citations
Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells.
Suyu Shu, Robert A. Krinock, Takafumi Matsumura, Jeffrey J. Sussman, Bernard A. Fox
Journal of Immunology. 1994-02-01

Press Mentions

Pebble Beach Cancer Researcher Has Paper Published in Medical JournalApril 18th, 2019
Sickle Cells Show Potential to Attack Aggressive Cancer TumorsJanuary 9th, 2013